We tested for additive effects of this genotype and case status on FKBP5 gex in Cohort 1 in all cases (combined to improve power) vs controls (T carrier/CC, control n = 108/64, schizophrenia n = 69/45, major depression n = 78/62, bipolar disorder n = 32/28; Online Resource, Supplementary Table 11). This evidence concerns the gene FKBP5 and schizophrenia.